This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Low, D. E.
Right arrow Articles by McGeer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Low, D. E.
Right arrow Articles by McGeer, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1295-1301, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1295-1301.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000

Donald E. Low,1,2* Joyce de Azavedo,1,2 Karl Weiss,3 Tony Mazzulli,1,2 Magdalena Kuhn,4 Deirdre Church,5 Kevin Forward,6 George Zhanel,7 Andrew Simor,8 Canadian Bacterial Surveillance Network,{dagger} and A. McGeer1,2

Department of Microbiology, Toronto Medical Laboratories and Mount Sinai Hospital,1 University of Toronto,2 Sunnybrooke and Women's College Health Sciences Center, Toronto, Ontario,8 Hopital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec,3 Southeast Healthcare Corporation-Moncton Site, Moncton, New Brunswick,4 Calgary Laboratory Services, Calgary, Alberta,5 Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia,6 Health Sciences Center, Winnipeg, Manitoba, Canada7

Received 15 October 2001/ Returned for modification 13 December 2001/ Accepted 24 January 2002

A total of 2,245 clinical isolates of Streptococcus pneumoniae were collected from 63 microbiology laboratories from across Canada during 2000 and characterized at a central laboratory. Of these isolates, 12.4% were not susceptible to penicillin (penicillin MIC, >=0.12 µg/ml) and 5.8% were resistant (MIC, >=2 µg/ml). Resistance rates among non-ß-lactam agents were the following: macrolides, 11.1%; clindamycin, 5.7%; chloramphenicol, 2.2%; levofloxacin, 0.9%; gatifloxacin, 0.8%; moxifloxacin, 0.4%; and trimethoprim-sulfamethoxazole, 11.3%. The MICs at which 90% of the isolates were inhibited (MIC90s) of the fluoroquinolones were the following: gemifloxacin, 0.03 µg/ml; BMS-284756, 0.06 µg/ml; moxifloxacin, 0.12 µg/ml; gatifloxacin, 0.25 µg/ml; levofloxacin, 1 µg/ml; and ciprofloxacin, 1 µg/ml. Of 578 isolates from the lower respiratory tract, 21 (3.6%) were inhibited at ciprofloxacin MICs of >=4 µg/ml. None of the 768 isolates from children were inhibited at ciprofloxacin MICs of >=4 µg/ml, compared to 3 of 731 (0.6%) from those ages 15 to 64 (all of these >60 years old), and 27 of 707 (3.8%) from those over 65. The MIC90s for ABT-773 and telithromycin were 0.015 µg/ml for macrolide-susceptible isolates and 0.12 and 0.5 µg/ml, respectively, for macrolide-resistant isolates. The MIC of linezolid was <=2 µg/ml for all isolates. Many of the new antimicrobial agents tested in this study appear to have potential for the treatment of multidrug-resistant strains of pneumococci.

* Corresponding author. Mailing address: Department of Microbiology, Rm. 1487, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario M5G 1X5, Canada. Phone: (416) 586-4435. Fax: (416) 586-8746. E-mail: dlow{at}mtsinai.on.ca.

{dagger} Members are listed in the Appendix.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1295-1301, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1295-1301.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wolter, N., Smith, A. M., Low, D. E., Klugman, K. P. (2007). High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 1092-1095 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Mohler, J., Bedos, J. P., Barau, C., Fantin, B. (2006). Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.. Antimicrob. Agents Chemother. 50: 3033-3038 [Abstract] [Full Text]  
  • Fukuda, Y., Yanagihara, K., Ohno, H., Higashiyama, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Mizuta, Y., Tashiro, T., Kohno, S. (2006). In Vivo Efficacies and Pharmacokinetics of DX-619, a Novel Des-Fluoro(6) Quinolone, against Streptococcus pneumoniae in a Mouse Lung Infection Model. Antimicrob. Agents Chemother. 50: 121-125 [Abstract] [Full Text]  
  • Monnet, D. L., Brandt, C. T., Kaltoft, M. S., Bagger-Skjot, L., Sorensen, T. L., Nielsen, H.-U. K., Frimodt-Moller, N. (2005). High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al. J Antimicrob Chemother 2005; 55: 748-57]. J Antimicrob Chemother 56: 433-434 [Full Text]  
  • Soley, C., Arguedas, A., Porras, W., Guevara, S., Loaiza, C., Perez, A., Rincon, G., Schultz, M., Arguedas, J., Brilla, R. (2005). In Vitro Activities of Levofloxacin and Comparable Agents against Middle Ear Fluid, Nasopharyngeal, and Oropharyngeal Pathogens Obtained from Costa Rican Children with Recurrent Otitis Media or Failing Other Antibiotic Therapy. Antimicrob. Agents Chemother. 49: 3056-3058 [Abstract] [Full Text]  
  • Granger, D., Boily-Larouche, G., Turgeon, P., Weiss, K., Roger, M. (2005). Genetic analysis of pbp2x in clinical Streptococcus pneumoniae isolates in Quebec, Canada. J Antimicrob Chemother 55: 832-839 [Abstract] [Full Text]  
  • Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother. 49: 188-194 [Abstract] [Full Text]  
  • Powis, J., McGeer, A., Green, K., Vanderkooi, O., Weiss, K., Zhanel, G., Mazzulli, T., Kuhn, M., Church, D., Davidson, R., Forward, K., Hoban, D., Simor, A., Low, D. E. (2004). In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002. Antimicrob. Agents Chemother. 48: 3305-3311 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Kipps, J., Zurlinden, E. (2004). Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin. Antimicrob. Agents Chemother. 48: 3508-3515 [Abstract] [Full Text]  
  • Song, J.-H., Jung, S.-I., Ko, K. S., Kim, N. Y., Son, J. S., Chang, H.-H., Ki, H. K., Oh, W. S., Suh, J. Y., Peck, K. R., Lee, N. Y., Yang, Y., Lu, Q., Chongthaleong, A., Chiu, C.-H., Lalitha, M. K., Perera, J., Yee, T. T., Kumarasinghe, G., Jamal, F., Kamarulzaman, A., Parasakthi, N., Van, P. H., Carlos, C., So, T., Ng, T. K., Shibl, A. (2004). High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study). Antimicrob. Agents Chemother. 48: 2101-2107 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Florea, N. R., Tessier, P. R., Zhang, C., Nightingale, C. H., Nicolau, D. P. (2004). Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 1215-1221 [Abstract] [Full Text]  
  • Low, D. E., Pichichero, M. E., Schaad, U. B. (2004). Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance. CLIN PEDIATR 43: 135-151 [Abstract]  
  • Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., Sato, K. (2003). In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3750-3759 [Abstract] [Full Text]  
  • Andes, D., Craig, W. A. (2003). Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model. Antimicrob. Agents Chemother. 47: 3935-3941 [Abstract] [Full Text]  
  • Davies, T. A., Goldschmidt, R., Pfleger, S., Loeloff, M., Bush, K., Sahm, D. F., Evangelista, A. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 52: 168-175 [Abstract] [Full Text]  
  • Chow, K. M., Szeto, C. C. (2003). Harbinger of Fluoroquinolone Resistance. Arch Intern Med 163: 1617-1617 [Full Text]  
  • Bingen, E., Doit, C., Loukil, C., Brahimi, N., Bidet, P., Deforche, D., Geslin, P. (2003). Activity of Telithromycin against Penicillin-Resistant Streptococcus pneumoniae Isolates Recovered from French Children with Invasive and Noninvasive Infections. Antimicrob. Agents Chemother. 47: 2345-2347 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y., Tyrrel, K. L., Fernandez, H. (2003). In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis. Antimicrob. Agents Chemother. 47: 1963-1967 [Abstract] [Full Text]  
  • Ross, J. J., Worthington, M. G., Gorbach, S. L., Tillotson, G. S., Zhao, X., Drlica, K., Zhanel, G. G., Hoban, D. J., Chan, C. K., Hutchinson, J., Low, D. E., de Azavedo, J., Bast, D. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 347: 65-67 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»